Holen Sie sich die Stockscreener-App
245.36
0.22%
0.55
Handel nachbörslich:
245.36
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$244.81
Offen:
$243.27
24-Stunden-Volumen:
773.89K
Relative Volume:
0.75
Marktkapitalisierung:
$35.81B
Einnahmen:
$5.26B
Nettoeinkommen (Verlust:
$1.44B
KGV:
25.11
EPS:
9.7713
Netto-Cashflow:
$1.76B
1W Leistung:
+1.03%
1M Leistung:
-4.36%
6M Leistung:
-4.51%
1J Leistung:
+5.91%
1-Tages-Spanne:
$242.54
$247.29
1-Wochen-Bereich:
$240.00
$247.29
52-Wochen-Spanne:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Vergleichen Sie RMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
245.36 | 35.73B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
ISRG
Intuitive Surgical Inc
|
566.38 | 199.22B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
198.96 | 55.54B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.65 | 38.12B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
39.00 | 31.97B | 27.43B | 1.27B | 1.01B | 1.5829 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Eingeleitet | Citigroup | Buy |
| 2025-09-02 | Hochstufung | CLSA | Hold → Outperform |
| 2025-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
ResMed Updates CDI and Share Structure for December 2025 - TipRanks
Insider Sell: Brett Sandercock Sells 1,000 Shares of ResMed Inc (RMD) - GuruFocus
ResMed Officer Brett Sandercock Discloses Planned Sale of 1,000 Shares Under Trading Plan - TipRanks
ResMed (NYSE:RMD) General Counsel Michael Rider Sells 50 Shares - MarketBeat
ResMed Q2 2026 Earnings Preview: EPS Growth Forecast & Analyst Rating | BarchartNews and Statistics - IndexBox
ResMed Inc. $RMD Shares Sold by TriaGen Wealth Management LLC - MarketBeat
What You Need to Know Ahead of ResMed's Earnings Release - Barchart.com
ResMed Inc.: How a Sleep-Tech Powerhouse Is Turning Data, Devices and Chronic Care Into a Platform P - AD HOC NEWS
Geopolitics Watch: Is ResMed Inc Common Stock RMEA stock overpriced at current multiplesWeekly Profit Summary & Weekly Return Optimization Plans - moha.gov.vn
ResMed Inc Reports Changes in CHESS Depositary Interests and Securities - MSN
ResMed Inc. (NYSE:RMD) is favoured by institutional owners who hold 69% of the company - simplywall.st
ResMed Inc. $RMD Shares Sold by Inspire Investing LLC - MarketBeat
Here's What ResMed's (NYSE:RMD) Strong Returns On Capital Mean - Yahoo Finance
ResMed Inc. Reports Changes in Beneficial Ownership - MSN
The Truth About ResMed Inc: Is This Sleep Tech Stock Quietly Going Viral? - AD HOC NEWS
ResMed (RMD) Product Pipeline Analysis Report 2025 – ResearchAndMarkets.com - The AI Journal
ResMed (RMD) Product Pipeline Analysis Report 2025ResearchAndMarkets.com - Bluefield Daily Telegraph
Is ResMed CDI (ASX:RMD) Still Shaping Value For Investors? - Kalkine Media
Ethic Inc. Raises Stock Holdings in ResMed Inc. $RMD - MarketBeat
Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
BSX vs. RMD: Which Medical Device Stock Is the Stronger Play Now? - The Globe and Mail
3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium - TradingView — Track All Markets
ResMed Inc announces proposed sale of securities by director - MSN
The Truth About ResMed Inc.: Is This Sleep Tech Stock the Next Viral Gamechanger or Just Hype? - AD HOC NEWS
ResMed Stock Breathes Easier as Sleep-Apnea Giant Outpaces the Market - AD HOC NEWS
ResMed Inc. $RMD Stock Holdings Raised by Pacer Advisors Inc. - MarketBeat
Why analysts maintain buy rating on ResMed Inc. (RME) stockGlobal Market Influence & Big Gains Small Capital - bollywoodhelpline.com
ResMed Officer Plans Further Share Sale Under Rule 144 - MSN
ResMed Inc. (NYSE:RMD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Voya Investment Management LLC Has $8.97 Million Position in ResMed Inc. $RMD - MarketBeat
Swedbank AB Increases Stock Position in ResMed Inc. $RMD - MarketBeat
Is ResMed stock underperforming the S&P 500? - MSN
Why ResMed (RMD) is a Top Growth Stock for the Long-Term - Yahoo Finance
OLD National Bancorp IN Increases Stock Holdings in ResMed Inc. $RMD - MarketBeat
Patton Fund Management Inc. Has $265,000 Stock Holdings in ResMed Inc. $RMD - MarketBeat
Confluence Investment Management LLC Sells 4,405 Shares of ResMed Inc. $RMD - MarketBeat
Thrivent Financial for Lutherans Acquires 5,212 Shares of ResMed Inc. $RMD - MarketBeat
The Bull Case For ResMed (RMD) Could Change Following FDA-Cleared AI Smart Comfort CPAP Feature - Sahm
Texas Permanent School Fund Corp Sells 5,560 Shares of ResMed Inc. $RMD - MarketBeat
Assenagon Asset Management S.A. Sells 5,635 Shares of ResMed Inc. $RMD - MarketBeat
Will ResMed Inc. (Common Stock) (RMEA) stock beat revenue estimatesPortfolio Performance Report & Intraday High Probability Alerts - ulpravda.ru
Technical Analysis: Will ResMed Inc. stock gain from strong economyTrend Reversal & Weekly High Return Stock Forecasts - ulpravda.ru
Is ResMed Inc. stock attractive for long term wealth buildingJuly 2025 Price Swings & Real-Time Volume Analysis - DonanımHaber
Will ResMed Inc. stock deliver better than expected guidanceJuly 2025 Movers & Long Hold Capital Preservation Tips - DonanımHaber
Resmed Inc Officer Plans Sale of Common Stock - MSN
Will ResMed Inc. stock attract more institutional investorsMarket Volume Report & Real-Time Volume Triggers - Улправда
Will ResMed Inc. stock benefit from automationQuarterly Trade Review & Growth-Oriented Investment Plans - DonanımHaber
Why ResMed Inc. stock is a value investor pickJuly 2025 Short Interest & Smart Money Movement Tracker - Улправда
ResMed Inc. $RMD Shares Acquired by Addenda Capital Inc. - MarketBeat
Healthcare Equipment Focus as ResMed Appears in ASX 100 Landscape - Kalkine Media
Is ResMed Inc. stock in correction or buying zoneJuly 2025 Setups & Daily Technical Forecast Reports - Улправда
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.93%
3.99%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):